HEPATIC INSUFFICIENT PATIENTS

EFFECT OF ALPRAZOLAM THERAPY ON LFT’s

Abstract

A lprazolam is principally metabolized by the liver. The effect of alprazolam therapy on LFT’s of fifteen hepatic
insufficient patients, was assessed and compared with five control subjects. Alprazolam, in a dose of 0.25 mg, B.D.,
was given for 21 days to fifteen male and female patients, with age group from 24-42 years, having weight from 45-60
Kg, and compared with five control subjects. The mean values of direct bilirubin in control and hepatic insufficient
patients were 0.25 mg% and 4.71 mg% on day zero, while on day 21, the values were 0.52 mg% and 4.42 mg%,
respectively. Total bilirubin was 0.76 mg% and 6.28 mg% on day zero and 0.53 mg% and 5.54 mg% on day 21 in
control and hepatic insufficient patients, respectively. The mean values of alkaline phosphatase (ALP) were 154.50
U/L on day zero and 169.20 U/L on day 21 in control group, while these were 626.40 U/L on day zero and 677.70
U/L on day 21, in hepatic insufficient patients. The mean values of serum glutamic pyruric trainsaminase (SGPT)
were 26 U/L on day zero and 27.40 U/L on day 21 in control group, while these were 48.0 U/L and 60.60 U/L on day
21 in hepatic insufficient patients. From above data, it was concluded that long term alprazolam therapy have no
effect on direct and total bilirubin but the values of ALP and SGPT increased.